Evidence map›Paper›PMID 21102478›Full record

ReviewAsian journal of andrology2011

Diagnostic tools in male infertility-the question of sperm dysfunction.

Christopher L R Barratt, Steven Mansell, Catherine Beaton, Steve Tardif, Senga K Oxenham

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Asian journal of andrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06188936 (Home Semen Analysis Tests As a Screening Tool for the Initial Assessment of Patients Referred to the Fertility Clinic), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06188936 early_phase1completednot on this mapstarted 2023, after this paper: background citation

Home Semen Analysis Tests As a Screening Tool for the Initial Assessment of Patients Referred to the Fertility Clinic: Assessing the Feasibility of a Randomised Trial in the UK

TypeinterventionalSponsorUniversity of AberdeenRan2023 to 2024Enrolled200ConditionsMale InfertilityArmsExSeed®, Survey
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Lack of trusted diagnostic tools for undetermined male infertility.Journal of assisted reproduction and genetics · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sperm function tests in clinical practice.Turkish journal of urology · 2017
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Engaging practicing gynecologists in the management of infertile men.Journal of obstetrics and gynaecology of India · 2015
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Christopher L R BarrattReproductive and Developmental Biology, Maternal and Child Health Science Laboratories, Centre for Oncology and Molecular Medicine, Ninewells Hospital, University of Dundee, Dundee, DD1 9SY, Scotland, UK. c.barratt@dundee.ac.uk
Steven Mansell
Catherine Beaton
Steve Tardif
Senga K Oxenham
Ninewells Hospital · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Sperm dysfunction is the single most common cause of infertility, yet what is remarkable is that, there is no drug a man can take or add to his spermatozoa in vitro to improve fertility. One reason for the lack of progress in this area is that our understanding of the cellular and molecular workings of the mature spermatazoon is limited. However, over the last few years there has been considerable progress in our knowledge base and in addressing new methods to diagnose sperm dysfunction. We review the current state of the field and provide insights for further development. We conclude that: (i) there is little to be gained from more studies identifying/categorizing various populations of men using a basic semen assessment, where an effort is required in making sure the analysis is performed in an appropriate high quality way; (ii) technological development is likely to bring the reality of sperm function testing closer to implementation into the clinical pathways. In doing this, these assays must be robust, cheap (or more appropriately termed cost effective), easy to use and clinically useful; and (iii) clinical necessity, e.g., the need to identify the highest quality spermatozoon for injection is driving basic research forward. This is an exciting time to be an andrologist and, likely, a fruitful one.

Indexed as

AnimalsHumansInfertility, MaleMaleSpermatozoaSperm Count

Identifiers

PMID21102478
PMCPMC3739390
OpenAlexW2089314043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.